Publications

  1. Singh B, Kung S, Poppe KA, Brown SL, Erickson C, Hale AM, Johnson BL, Jones KL, Pazdernik VK, Schak KM, Betcher HK, Moore KM, Ozerdem A, Veldic M, Frye MA, Bobo WV. Partial wake therapy and luminotherapy as an adjunct to usual care in hospitalized patients with depression - a pilot study. Psychiatry Res 2024 Jul; 337:115921 Epub 2024 Apr 25
    View PubMed
  2. Joseph B, Nunez NA, Kung S, Vande Voort JL, Pazdernik VK, Schak KM, Boehm SM, Carpenter B, Johnson EK, Malyshev G, Smits N, Adewunmi DO, Brown SK, Singh B. Correction: Joseph et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals 2023, 16, 1164. Pharmaceuticals (Basel). 2023 Nov 7; 16 (11) Epub 2023 Nov 07
    View PubMed
  3. Joseph B, Nunez NA, Kung S, Vande Voort JL, Pazdernik VK, Schak KM, Boehm SM, Carpenter B, Johnson EK, Malyshev G, Smits N, Adewunmi DO, Brown SK, Singh B. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals (Basel). 2023 Aug 16; 16 (8)
    View PubMed
  4. Singh B, Kung S, Pazdernik V, Schak KM, Geske J, Schulte PJ, Frye MA, Vande Voort JL. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study. J Clin Psychiatry. 2023 Feb 1; 84 (2) Epub 2023 Feb 01
    View PubMed
  5. Singh B, Kung S, Schak KM, Bobo WV, Frye MA, Vande Voort JL. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Real-World Setting Among Patients with Treatment Refractory Depression. CNS Spectr. 2022 Apr; 27 (2):232
    View PubMed
  6. Skime MK, Puspitasari AJ, Gentry MT, Heredia D Jr, Sawchuk CN, Moore WR, Taylor-Desir MJ, Schak KM. Patient Satisfaction and Recommendations for Delivering a Group-Based Intensive Outpatient Program via Telemental Health During the COVID-19 Pandemic: Cross-sectional Cohort Study. JMIR Ment Health. 2022 Jan 28; 9 (1):e30204
    View PubMed
  7. Puspitasari AJ, Heredia D Jr, Gentry M, Sawchuk C, Theobald B, Moore W, Tiede M, Galardy C, Schak K. Rapid Adoption and Implementation of Telehealth Group Psychotherapy During COVID 19: Practical Strategies and Recommendations. Cogn Behav Pract. 2021 Nov; 28 (4):492-506 Epub 2021 June 24
    View PubMed
  8. Leung JG, Owen A, Webb AJ, Johnson EK, Dively-White M, Kreps M, Anderson KK, Schak KM. Improvement of Inpatient Psychiatric Facility Quality Reporting program measure: Screening for metabolic disorders through pharmacy collaborative practice agreement. J Am Pharm Assoc (2003). 2021 Sep-Oct; 61 (5):e126-e131 Epub 2021 Apr 21
    View PubMed
  9. Palmer BA, Pahwa M, Geske JR, Kung S, Nassan M, Schak KM, Alarcon RD, Frye MA, Singh B. Self-report screening instruments differentiate bipolar disorder and borderline personality disorder. Brain Behav. 2021 Jul; 11 (7):e02201 Epub 2021 May 30
    View PubMed
  10. Gandhi KD, Schak KM, Vande JL, Shekunov J, Lynch BA, Rummans TA, Geske JR, Pease ER, Limbeck MG, Desai J, Croarkin PE, Romanowicz M. The Negative Impact of Maternal Perinatal Opioid Use on Neonatal Outcomes. Prim Care Companion CNS Disord. 2021 Jun 10; 23 (3) Epub 2021 June 10
    View PubMed
  11. Puspitasari AJ, Heredia D, Coombes BJ, Geske JR, Gentry MT, Moore WR, Sawchuk CN, Schak KM. Feasibility and Initial Outcomes of a Group-Based Teletherapy Psychiatric Day Program for Adults With Serious Mental Illness: Open, Nonrandomized Trial in the Context of COVID-19. JMIR Ment Health. 2021 Mar 11; 8 (3):e25542
    View PubMed
  12. Dimeff LA, Jobes DA, Koerner K, Kako N, Jerome T, Kelley-Brimer A, Boudreaux ED, Beadnell B, Goering P, Witterholt S, Melin G, Samike V, Schak KM. Using a Tablet-Based App to Deliver Evidence-Based Practices for Suicidal Patients in the Emergency Department: Pilot Randomized Controlled Trial. JMIR Ment Health. 2021 Mar 1; 8 (3):e23022 Epub 2021 Mar 01
    View PubMed
  13. Romanowicz M, Schak KM, Vande Voort JL, Leung JG, Larrabee BR, Palmer BA. Prescribing Practices for Patients With Borderline Personality Disorder During Psychiatric Hospitalizations. J Pers Disord. 2020 Dec; 34 (6):736-749 Epub 2019 Feb 11
    View PubMed
  14. Nunez NA, Joseph B, Pahwa M, Seshadri A, Prokop LJ, Kung S, Schak KM, Vande Voort JL, Frye MA, Singh B. An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis. Psychopharmacol Bull. 2020 Sep 14; 50 (4):137-163
    View PubMed
  15. Leung JG, Wittenberger TS, Schak KM. Clozapine treated patients and COVID-19: Ensuring continued care through collaboration. Schizophr Res 2020 Aug; 222:507-508 Epub 2020 May 14
    View PubMed
  16. Sonmez AI, Kucuker MU, Kolla BP, Lewis CP, Kolla BP, Doruk Camsari D, Vande Voort JL, Schak KM, Kung S, Croarkin PE. Improvement in hypersomnia with high frequency repetitive transcranial magnetic stimulation in depressed adolescents: Preliminary evidence from an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Mar 8; 97:109763 Epub 2019 Oct 18
    View PubMed
  17. Leung JG, Kutzke JL, Morgan RJ, Schak KM. Thrombocytopenia associated with clonidine in a case of clozapine-induced sialorrhea. Ment Health Clin. 2020 Jan; 10 (1):34-37 Epub 2020 Jan 09
    View PubMed
  18. Singh B, Bobo WV, Rasmussen KG, Stoppel CJ, Rico JA Jr, Schak KM, Biernacka JM, Frye MA, Vande Voort JL. The Association Between Body Mass Index and Remission Rates in Patients With Treatment-Resistant Depression Who Received Intravenous Ketamine. J Clin Psychiatry 2019 Nov 12; 80 (6)
    View PubMed
  19. Romanowicz M, Vande Voort JL, Shekunov J, Oesterle TS, Thusius NJ, Rummans TA, Croarkin PE, Karpyak VM, Lynch BA, Schak KM. The effects of parental opioid use on the parent-child relationship and children's developmental and behavioral outcomes: a systematic review of published reports. Child Adolesc Psychiatry Ment Health. 2019; 13:5 Epub 2019 Jan 12
    View PubMed
  20. Steinauer LM, Leung JG, Burkey BW, McGrane IR, Letts V, Goren JL, Hoeft DM, Mullen S, Maroney M, Schak KM, Vande Voort JL. A Retrospective Multicenter Evaluation of Clozapine Use in Pediatric Patients Admitted for Acute Psychiatric Hospitalization. J Child Adolesc Psychopharmacol. 2018 Nov; 28 (9):615-619 Epub 2018 Oct 24
    View PubMed
  21. Markota M, McKean AJ, Romanowicz M, Schak KM, Croarkin PE, Vande Voort JL. Rehospitalization to a child and adolescent psychiatry unit: Role of trauma and bullying. Gen Hosp Psychiatry. 2018 Nov - Dec; 55:10-14 Epub 2018 Aug 30
    View PubMed
  22. Croarkin PE, Nakonezny PA, Deng ZD, Romanowicz M, Voort JLV, Camsari DD, Schak KM, Port JD, Lewis CP. High-frequency repetitive TMS for suicidal ideation in adolescents with depression. J Affect Disord. 2018 Oct 15; 239:282-290 Epub 2018 July 18
    View PubMed
  23. Schmidt KA, Lamoureux IC, Schak KM, Lachner C, Burton MC, Larrabee BR, Rummans TA. Substance use disorders and their effect on the psychiatric and justice systems. Am J Addict. 2018 Oct; 27 (7):574-577 Epub 2018 Aug 28
    View PubMed
  24. Knoph KN, Morgan RJ 3rd, Palmer BA, Schak KM, Owen AC, Leloux MR, Patel M, Leung JG. Clozapine-induced cardiomyopathy and myocarditis monitoring: A systematic review. Schizophr Res. 2018 Sep; 199:17-30 Epub 2018 Mar 13
    View PubMed
  25. Warren MB, Schak KM. Disclosing Huntington's Genetic Testing Results in the Context of Intellectual Disability and Guardianship: Using the Family Illness Narrative to Guide the Flow of Information. J Genet Couns. 2017 Apr; 26 (2):272-275 Epub 2016 Oct 15
    View PubMed
  26. Gonzalez SD, Williams AJ, Blacker CJ, Vande Voort JL, Schak KM, Nemeroff CB, Widge AK, Tohen M. Putative biological predictors of treatment response in bipolar disorders Personalized Medicine in Psychiatry.2017;1:(2):39-58.
  27. Vande Voort JL, Morgan RJ, Kung S, Rasmussen KG, Rico J, Palmer BA, Schak KM, Tye SJ, Ritter MJ, Frye MA, Bobo WV. Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord. 2016 Dec; 206:300-304. Epub 2016 Sep 12.
    View PubMed
  28. Vande Voort JL, Singh A, Bernardi J, Wall CA, Swintak CC, Schak KM, Jensen PS. Treatments and Services Provided to Children Diagnosed with Bipolar Disorder. Child Psychiatry Hum Dev. 2016 Jun; 47 (3):494-502
    View PubMed
  29. Schak KM, Vande Voort JL, Johnson EK, Kung S, Leung JG, Rasmussen KG, Palmer BA, Frye MA. Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment. Am J Psychiatry. 2016 Mar 1; 173 (3):215-8
    View PubMed
  30. Frye MA, McElroy SL, Fuentes M, Sutor B, Schak KM, Galardy CW, Palmer BA, Prieto ML, Kung S, Sola CL, Ryu E, Veldic M, Geske J, Cuellar-Barboza A, Seymour LR, Mori N, Crowe S, Rummans TA, Biernacka JM. Development of a bipolar disorder biobank: differential phenotyping for subsequent biomarker analyses. Int J Bipolar Disord. 2015 Dec; 3 (1):30 Epub 2015 June 24
    View PubMed
  31. McKean AJ, Leung JG, Dare FY, Sola CL, Schak KM. The Perils of Illegitimate Online Pharmacies: Substance-Induced Panic Attacks and Mood Instability Associated With Selegiline and Phenylethylamine. Psychosomatics. 2015 Sep-Oct; 56: (5)583-7.
    View PubMed
  32. Leung JG, Hall-Flavin D, Nelson S, Schmidt KA, Schak KM. The role of gabapentin in the management of alcohol withdrawal and dependence. Ann Pharmacother. 2015 Aug; 49 (8):897-906 Epub 2015 May 12
    View PubMed
  33. Angstman KB, Phelan S, Myszkowski MR, Schak KM, DeJesus RS, Lineberry TW, van Ryn M. Minority Primary Care Patients With Depression: Outcome Disparities Improve With Collaborative Care Management. Med Care. 2015 Jan; 53 (1):32-7
    View PubMed
  34. Silverman MA, Leung JG, Schak KM. Aripiprazole-associated hiccups: a case and closer look at the association between hiccups and antipsychotics. J Pharm Pract. 2014 Dec; 27(6):587-90. Epub 2014 Aug 08.
    View PubMed
  35. Bryan CJ, Hitschfeld MJ, Palmer BA, Schak KM, Roberge EM, Lineberry TW. Gender differences in the association of agitation and suicide attempts among psychiatric inpatients. Gen Hosp Psychiatry. 2014 Nov-Dec; 36(6):726-31. Epub 2014 Sep 28.
    View PubMed
  36. Romanowicz M, O'Connor SS, Schak KM, Swintak CC, Lineberry TW. Use of the Suicide Status Form-II to investigate correlates of suicide risk factors in psychiatrically hospitalized children and adolescents. J Affect Disord. 2013 Nov; 151 (2):467-473 Epub 2013 July 13
    View PubMed
  37. Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, Ritter MJ, Schak KM, Sola CL, Hanson AJ, Frye MA. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol. 2013 May; 27 (5):444-50 Epub 2013 Feb 20
    View PubMed
  38. Sim LA, Homme JH, Lteif AN, Vande Voort JL, Schak KM, Ellingson J. Family functioning and maternal distress in adolescent girls with anorexia nervosa. Int J Eat Disord. 2009 Sep; 42(6):531-9.
    View PubMed
  39. Schak KM, Mueller PS, Barnes RD, Rasmussen KG. The safety of ECT in patients with chronic obstructive pulmonary disease. Psychosomatics. 2008 May-Jun; 49(3):208-11.
    View PubMed
  40. Mueller PS, Schak KM, Barnes RD, Rasmussen KG. Safety of electroconvulsive therapy in patients with asthma. Neth J Med. 2006 Dec; 64(11):417-21.
    View PubMed
  41. Van Sickle BJ, Cox AS, Schak K, Greenfield LJ Jr, Tietz EI. Chronic benzodiazepine administration alters hippocampal CA1 neuron excitability: NMDA receptor function and expression(1). Neuropharmacology. 2002 Sep; 43(4):595-606.
    View PubMed
  42. Schak KM, Scordilis SP, Ferreyra GA, Harrington ME. Neuropeptide Y activates protein kinase C in hamster suprachiasmatic nuclei brain slices. Biological Rhythm Research. 2001; 32(2):201-6.
  43. Harrington ME, Schak KM. Neuropeptide Y phase advances the in vitro hamster circadian clock during the subjective day with no effect on phase during the subjective night. Can J Physiol Pharmacol. 2000 Feb; 78(2):87-92.
    View PubMed
  44. Schak KM, Harrington ME. Protein kinase C inhibition and activation phase advances the hamster circadian clock. Brain Res. 1999 Sep 4; 840(1-2):158-61.
    View PubMed
  45. Lee JM, Schak KM, Harrington ME. Inhibition of protein kinase A phase delays the mammalian circadian clock. Brain Res. 1999 Jul 24; 835(2):350-3.
    View PubMed
  46. Biello SM, Golombek DA, Schak KM, Harrington ME. Circadian phase shifts to neuropeptide Y In vitro: cellular communication and signal transduction. J Neurosci. 1997 Nov 1; 17(21):8468-75.
    View PubMed